Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study proposes to provide adequate treatment and is based on current scientific evidence
for elderly patients with ALL Bcr / Abl positive.
To determine whether low-dose chemotherapy associated with imatinib or dasatinib has
acceptable tolerability in elderly patients.
To determine whether this association can increase the rate and quality of referrals to the
results of the literature of imatinib as monotherapy for elderly patients